Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer
Abstract Ovarian cancer ranks as the eighth most common malignancy in women globally. Early detection remains a critical challenge for improving ovarian cancer diagnosis and treatment outcomes. Our prior study demonstrated that ARHGAP40 downregulation in basal cell carcinoma is attributed to CpG isl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-025-01729-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238484544389120 |
|---|---|
| author | Jiaxin Chai Dongni Leng Shuwei Guo Rusong Zhang Jiandong Wang Yun Gu Qiu Rao |
| author_facet | Jiaxin Chai Dongni Leng Shuwei Guo Rusong Zhang Jiandong Wang Yun Gu Qiu Rao |
| author_sort | Jiaxin Chai |
| collection | DOAJ |
| description | Abstract Ovarian cancer ranks as the eighth most common malignancy in women globally. Early detection remains a critical challenge for improving ovarian cancer diagnosis and treatment outcomes. Our prior study demonstrated that ARHGAP40 downregulation in basal cell carcinoma is attributed to CpG island hypermethylation. However, the expression and methylation status of ARHGAP40 in ovarian cancer remain unexplored. Here, we investigated ARHGAP40 protein expression in normal fallopian tubes, ovarian benign tumors, borderline tumors, low-grade serous carcinoma (LGSC) and high-grade serous carcinomas (HGSC). Methylation analysis of the ARHGAP40 was performed using bisulfite sequencing PCR (BSP). MethyLight assays were developed to detect methylated circulating tumor DNA (ctDNA) fragments of ARHGAP40. IHC results revealed absent or weak ARHGAP40 protein expression in 93.8% (30/32) of HGSC, 11.1% (2/18) of borderline tumors, and in 14.3% (1/7) of LGSC cases. ARHGAP40 protein expression was robust expressed in all normal fallopian tubes (15/15) and benign ovarian tumors (8/8). CpG island hypermethylation in the ARHGAP40 promoter showed a strong inverse correlation with protein expression (P < 0.001). Furthermore, methylated ctDNA for ARHGAP40 was detected in 80.0% (4/5) of HGSC patients’ plasma, but not in benign tumor (0/3) and healthy controls (0/15). Our findings suggest that promoter hypermethylation may be a mechanism underlying ARHGAP40 silencing in HGSC. Detection of methylated ARHGAP40 ctDNA may serve as a noninvasive biomarker for early diagnosis and monitoring of HGSC. While our findings suggest the potential of methylated ARHGAP40 as an early diagnostic biomarker, the small sample size warrants validation in larger cohorts. |
| format | Article |
| id | doaj-art-c044b2e4c5ec44c599d9f4088ed5a02a |
| institution | Kabale University |
| issn | 1757-2215 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj-art-c044b2e4c5ec44c599d9f4088ed5a02a2025-08-20T04:01:35ZengBMCJournal of Ovarian Research1757-22152025-07-011811810.1186/s13048-025-01729-9Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancerJiaxin Chai0Dongni Leng1Shuwei Guo2Rusong Zhang3Jiandong Wang4Yun Gu5Qiu Rao6Department of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Pathology, Nanjing JunXie HospitalDepartment of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Pathology, Women’s Hospital of Nanjing Medical University, Nanjing Women and Children’s Healthcare HospitalDepartment of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityAbstract Ovarian cancer ranks as the eighth most common malignancy in women globally. Early detection remains a critical challenge for improving ovarian cancer diagnosis and treatment outcomes. Our prior study demonstrated that ARHGAP40 downregulation in basal cell carcinoma is attributed to CpG island hypermethylation. However, the expression and methylation status of ARHGAP40 in ovarian cancer remain unexplored. Here, we investigated ARHGAP40 protein expression in normal fallopian tubes, ovarian benign tumors, borderline tumors, low-grade serous carcinoma (LGSC) and high-grade serous carcinomas (HGSC). Methylation analysis of the ARHGAP40 was performed using bisulfite sequencing PCR (BSP). MethyLight assays were developed to detect methylated circulating tumor DNA (ctDNA) fragments of ARHGAP40. IHC results revealed absent or weak ARHGAP40 protein expression in 93.8% (30/32) of HGSC, 11.1% (2/18) of borderline tumors, and in 14.3% (1/7) of LGSC cases. ARHGAP40 protein expression was robust expressed in all normal fallopian tubes (15/15) and benign ovarian tumors (8/8). CpG island hypermethylation in the ARHGAP40 promoter showed a strong inverse correlation with protein expression (P < 0.001). Furthermore, methylated ctDNA for ARHGAP40 was detected in 80.0% (4/5) of HGSC patients’ plasma, but not in benign tumor (0/3) and healthy controls (0/15). Our findings suggest that promoter hypermethylation may be a mechanism underlying ARHGAP40 silencing in HGSC. Detection of methylated ARHGAP40 ctDNA may serve as a noninvasive biomarker for early diagnosis and monitoring of HGSC. While our findings suggest the potential of methylated ARHGAP40 as an early diagnostic biomarker, the small sample size warrants validation in larger cohorts.https://doi.org/10.1186/s13048-025-01729-9Ovarian cancerARHGAP40Methylation, CfDNACtDNA |
| spellingShingle | Jiaxin Chai Dongni Leng Shuwei Guo Rusong Zhang Jiandong Wang Yun Gu Qiu Rao Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer Journal of Ovarian Research Ovarian cancer ARHGAP40 Methylation, CfDNA CtDNA |
| title | Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer |
| title_full | Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer |
| title_fullStr | Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer |
| title_full_unstemmed | Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer |
| title_short | Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer |
| title_sort | methylated arhgap40 dna as a potential biomarker for early diagnosis in high grade ovarian serous cancer |
| topic | Ovarian cancer ARHGAP40 Methylation, CfDNA CtDNA |
| url | https://doi.org/10.1186/s13048-025-01729-9 |
| work_keys_str_mv | AT jiaxinchai methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT dongnileng methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT shuweiguo methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT rusongzhang methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT jiandongwang methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT yungu methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer AT qiurao methylatedarhgap40dnaasapotentialbiomarkerforearlydiagnosisinhighgradeovarianserouscancer |